Bernabeu-Wittel, 272 patient HCQ early treatment study: 59% lower mortality [p=0.03] https://c19p.org/bernabeuwittel
copied to clipboard
Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks
et al., J. Gerontol. A Biol. Sci. Med. Sci., doi:10.1093/gerona/glaa192
Retrospective 272 nursing home residents showing significantly improved survival after establishing a treatment program including HCQ with or without lopinavir/ritonavir and with the addition of adjuvant and antimicrobial treatments depending on circumstances. Dosage details are in the supplementary appendix. Mortality relative risk is from [Alexander].
|
risk of death, 59.0% lower, RR 0.41, p = 0.03, treatment 189, control 83.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Bernabeu-Wittel et al., 8/1/2020, retrospective, Spain, Europe, peer-reviewed, 13 authors, dosage 400mg bid day 1, 200mg bid days 2-7, this trial uses multiple treatments in the treatment arm (combined with lopinavir/ritonavir and antimicrobial treatments) - results of individual treatments may vary.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.